BioSpace News Archive

Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, today announced the appointment of Karimah Es Sabar to its Board of Directors, effective immediately.

SANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that a poster by Christopher L Reading, PhD, BioVie’s Executive Vice President for Neuroscience Research & Development was presented at the 2021 Alzheimer’s Association International Conference (AAIC). Poster 55458 entitled “Rationale for an anti-inflammatory i

AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS’ anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021.

A new study found computerized brain exercises – the BrainHQ app from Posit Science – drove significant improvement in overall cognition and can be administered remotely in patient’s homes.

AliveCor, Inc. (“AliveCor”), and Acutus Medical (“Acutus”) (Nasdaq: AFIB), today announced they will collaborate to assess the integration of data collection tools across the cardiology continuum of care that could potentially advance the field of arrhythmia treatment and disease management.

ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

RareStone Inc., formerly Citrine Medicine, a China-based rare disease company, and Tencent Holdings Limited (Tencent), based in Shenzhen, China, signed a strategic collaboration memorandum to develop a service ecosystem focused on rare disease patients in China.

nference, the AI-driven health technology company, today announced publication of a study in npj Digital Medicine which establishes relationships between specific pre-existing conditions and complications from COVID-19 infection, in an effort to better identify which patients will develop severe disease.

Dyadic International, Inc., announced it signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, a South African-based company whose mission is to develop a South African-based solution for the discovery, development, evaluation and manufacture of high-quality, cost-effective vaccines for distribution primarily to the African markets.